FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385697992> ?p ?o ?g. }

• W4385697992 endingPage "e402511c" @default.
• W4385697992 startingPage "e402511c" @default.
• W4385697992 abstract "Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Patients (pts) with diffuse large B-cell lymphoma (DLBCL) who relapse after stem cell transplant or chimeric antigen receptor therapy or are refractory to second-line therapy have poor prognosis and few treatment options (Chow et al. 2019). For these pts, long-term disease control with manageable toxicity is the goal. Loncastuximab tesirine (loncastuximab tesirine-lpyl; Lonca), an anti-CD19 antibody conjugated to a pyrrolobenzodiazepine dimer, demonstrated single-agent antitumor activity in LOTIS-2, the pivotal phase 2 study in heavily pretreated pts with relapsed/refractory (R/R) DLBCL (Caimi et al. 2021). In previously presented follow-up analyses (median follow-up: 7.8 months [mo; range: 0.3, 31.0]), durable responses to Lonca were observed (median duration of response [mDOR]: 13.4 mo; median duration of complete response [CR]: not reached [NR]; Zinzani et al. ICML 2021). Aims: To present updated long-term efficacy and safety from LOTIS-2 (NCT03589469) in pts with R/R DLBCL treated with Lonca, including subsets of pts with durable CR. Methods: LOTIS-2 was a multicenter, open-label, single-arm phase 2 study of Lonca monotherapy in pts with R/R DLBCL after ≥2 prior systemic therapies. Lonca was administered every 3 weeks (150 µg/kg for 2 cycles; 75 µg/kg thereafter). The primary efficacy endpoint was overall response rate (Lugano 2014 criteria). Secondary endpoints included DOR; CR rate; and relapse-free, progression-free (PFS; measured from start of therapy), and overall survival (OS). Efficacy and safety analyses were performed for all pts and subsets of pts with CR, and pts with CR who were event-free (no progressive disease or death) for ≥1 and ≥2 years (yr) from cycle 1, day 1. Results: As of final data cutoff (September 15, 2022; median follow-up: 7.8 mo [range: 0.3, 42.6]), 70 (48%) of 145 pts achieved response and 36 (25%) pts achieved CR; 16 (44%) and 11 (31%) of the 36 CR pts were event-free for ≥1 and ≥2 yr, respectively. Median numbers of doses were 12.5 and 13.0 for pts with CR who were event-free for ≥1 and ≥2 yr, respectively. All 11 pts with CR who were event-free for ≥2 yr were censored at study end. Among all pts, the mDOR was 13.4 mo (95% CI: 6.9, -), mPFS 4.9 mo (2.9, 8.3), and mOS 9.5 mo (6.7, 11.5). Among pts with CR, the mDOR, mPFS, and mOS were NR (Figure 1). All-grade treatment-emergent adverse events occurring in ≥30% of all pts were increased gamma-glutamyltransferase (42%), neutropenia (40%), and thrombocytopenia (33%). Summary/Conclusion: Among heavily pretreated pts in LOTIS-2, Lonca continued to demonstrate durable, long-term responses in pts with CR with a manageable safety profile; 31% of the 36 CR pts were event-free for ≥2 yr with no evidence of disease and no new anticancer therapy post-Lonca. Further study is needed to identify factors predictive of long-term response to Lonca. Funding: ADC Therapeutics SA; medical writing: CiTRUS Health Group.Keywords: Diffuse large B cell lymphoma, CD19, Long-term follow-up" @default.
• W4385697992 created "2023-08-10" @default.
• W4385697992 creator A5002943174 @default.
• W4385697992 creator A5004066032 @default.
• W4385697992 creator A5011030256 @default.
• W4385697992 creator A5016048836 @default.
• W4385697992 creator A5035541800 @default.
• W4385697992 creator A5042459008 @default.
• W4385697992 creator A5044447212 @default.
• W4385697992 creator A5048622832 @default.
• W4385697992 creator A5050290286 @default.
• W4385697992 creator A5053161231 @default.
• W4385697992 creator A5059145854 @default.
• W4385697992 creator A5069054551 @default.
• W4385697992 creator A5071494334 @default.
• W4385697992 creator A5079899240 @default.
• W4385697992 creator A5091882595 @default.
• W4385697992 creator A5092085016 @default.
• W4385697992 date "2023-08-01" @default.
• W4385697992 modified "2023-10-16" @default.
• W4385697992 title "P1132: LONG-TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS-2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA" @default.
• W4385697992 doi "https://doi.org/10.1097/01.hs9.0000971424.40251.1c" @default.
• W4385697992 hasPublicationYear "2023" @default.
• W4385697992 type Work @default.
• W4385697992 citedByCount "0" @default.
• W4385697992 crossrefType "journal-article" @default.
• W4385697992 hasAuthorship W4385697992A5002943174 @default.
• W4385697992 hasAuthorship W4385697992A5004066032 @default.
• W4385697992 hasAuthorship W4385697992A5011030256 @default.
• W4385697992 hasAuthorship W4385697992A5016048836 @default.
• W4385697992 hasAuthorship W4385697992A5035541800 @default.
• W4385697992 hasAuthorship W4385697992A5042459008 @default.
• W4385697992 hasAuthorship W4385697992A5044447212 @default.
• W4385697992 hasAuthorship W4385697992A5048622832 @default.
• W4385697992 hasAuthorship W4385697992A5050290286 @default.
• W4385697992 hasAuthorship W4385697992A5053161231 @default.
• W4385697992 hasAuthorship W4385697992A5059145854 @default.
• W4385697992 hasAuthorship W4385697992A5069054551 @default.
• W4385697992 hasAuthorship W4385697992A5071494334 @default.
• W4385697992 hasAuthorship W4385697992A5079899240 @default.
• W4385697992 hasAuthorship W4385697992A5091882595 @default.
• W4385697992 hasAuthorship W4385697992A5092085016 @default.
• W4385697992 hasBestOaLocation W43856979921 @default.
• W4385697992 hasConcept C126322002 @default.
• W4385697992 hasConcept C141071460 @default.
• W4385697992 hasConcept C142424586 @default.
• W4385697992 hasConcept C143998085 @default.
• W4385697992 hasConcept C203092338 @default.
• W4385697992 hasConcept C2778559949 @default.
• W4385697992 hasConcept C2779338263 @default.
• W4385697992 hasConcept C29730261 @default.
• W4385697992 hasConcept C31760486 @default.
• W4385697992 hasConcept C535046627 @default.
• W4385697992 hasConcept C71924100 @default.
• W4385697992 hasConcept C86803240 @default.
• W4385697992 hasConcept C87355193 @default.
• W4385697992 hasConcept C90924648 @default.
• W4385697992 hasConceptScore W4385697992C126322002 @default.
• W4385697992 hasConceptScore W4385697992C141071460 @default.
• W4385697992 hasConceptScore W4385697992C142424586 @default.
• W4385697992 hasConceptScore W4385697992C143998085 @default.
• W4385697992 hasConceptScore W4385697992C203092338 @default.
• W4385697992 hasConceptScore W4385697992C2778559949 @default.
• W4385697992 hasConceptScore W4385697992C2779338263 @default.
• W4385697992 hasConceptScore W4385697992C29730261 @default.
• W4385697992 hasConceptScore W4385697992C31760486 @default.
• W4385697992 hasConceptScore W4385697992C535046627 @default.
• W4385697992 hasConceptScore W4385697992C71924100 @default.
• W4385697992 hasConceptScore W4385697992C86803240 @default.
• W4385697992 hasConceptScore W4385697992C87355193 @default.
• W4385697992 hasConceptScore W4385697992C90924648 @default.
• W4385697992 hasIssue "S3" @default.
• W4385697992 hasLocation W43856979921 @default.
• W4385697992 hasLocation W43856979922 @default.
• W4385697992 hasOpenAccess W4385697992 @default.
• W4385697992 hasPrimaryLocation W43856979921 @default.
• W4385697992 hasRelatedWork W2003938723 @default.
• W4385697992 hasRelatedWork W2047967234 @default.
• W4385697992 hasRelatedWork W2070148911 @default.
• W4385697992 hasRelatedWork W2118496982 @default.
• W4385697992 hasRelatedWork W2351796763 @default.
• W4385697992 hasRelatedWork W2439875401 @default.
• W4385697992 hasRelatedWork W3162448531 @default.
• W4385697992 hasRelatedWork W3182090251 @default.
• W4385697992 hasRelatedWork W4238867864 @default.
• W4385697992 hasRelatedWork W2525756941 @default.
• W4385697992 hasVolume "7" @default.
• W4385697992 isParatext "false" @default.
• W4385697992 isRetracted "false" @default.
• W4385697992 workType "article" @default.